Effects of low-dose niacin on dyslipidemia and serum phosphorus in patients with chronic kidney disease.
- Author:
Hyo Jin KANG
1
;
Do Kyong KIM
;
Su Mi LEE
;
Kyung Han KIM
;
Seung Hee HAN
;
Ki Hyun KIM
;
Seong Eun KIM
;
Young Ki SON
;
Won Suk ANN
Author Information
1. Department of Internal Medicine, Dong-A University Medical School, Busan, Korea. anws@dau.ac.kr
- Publication Type:Original Article
- Keywords:
Adverse effects;
Dyslipidemia;
Glomerular filtration rate;
Niacin;
Phosphorus
- MeSH:
Cholesterol;
Dyslipidemias;
Fatty Acids, Omega-3;
Glomerular Filtration Rate;
Humans;
Hydroxymethylglutaryl-CoA Reductase Inhibitors;
Lipoproteins;
Niacin;
Phosphorus;
Renal Insufficiency, Chronic;
Retrospective Studies
- From:Kidney Research and Clinical Practice
2013;32(1):21-26
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND: Niacin supplementation improves dyslipidemia and lowers serum phosphorus levels in patients with chronic kidney disease (CKD). We evaluated whether low-dose niacin supplementation can improve dyslipidemia, lower serum phosphorus levels, and be administered with a low frequency of adverse effects in patients with CKD. METHODS: We retrospectively analyzed the clinical records of patients with CKD who had taken niacin from January 2009 to June 2011. We excluded patients with CKD stage 1 and 5. We then enrolled 31 patients with CKD who had taken niacin at a fixed dose of 500mg/day for 6 months. We also randomly selected 30 patients with CKD who had been taking statin for 9 months as a control group. RESULTS: Among the 34 patients with CKD who were prescribed niacin, five (14%) complained of adverse effects, and three (8%) discontinued niacin. The proportion of patients in the niacin group who had been taking a statin or omega-3 fatty acids was 67.7% and 48.8%, respectively. In the niacin group, high-density lipoprotein cholesterol level was significantly increased and triglyceride level was significantly decreased at 12 and 24 weeks compared with baseline levels (P < 0.05). In the niacin group, phosphorous level (P < 0.05) was significantly decreased, and glomerular filtration rate (GFR) was significantly increased (P < 0.05) at 24 weeks compared with baseline values. CONCLUSION: Low-dose niacin had a low frequency of adverse effects and also improved dyslipidemia, lowered serum phosphorus level, and increased GFR in patients with CKD. Further studies are needed to evaluate the long-term effects of low-dose niacin for renal progression of CKD.
